Keywords: USA, FDA panel, Regeneron, Arcalyst, Gout flares, Otsuka, Abilify, Patent, Bristol-Myers

USA: FDA panel votes against Regeneron gout drug; Court upholds Abilify patent

Article | 09 May 2012

Print This

The US Food and Drug Administration’s Arthritis Advisory Committee yesterday voted unanimously (11 to 0) against approval of US drugmaker ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in